Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Hold” from Brokerages

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have been assigned a consensus recommendation of “Hold” from the nine research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.75.

A number of research firms recently weighed in on INZY. Needham & Company LLC cut Inozyme Pharma from a “moderate buy” rating to a “hold” rating in a report on Friday, May 16th. Raymond James dropped their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Inozyme Pharma in a report on Thursday, April 10th. Wedbush downgraded Inozyme Pharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 16th. Finally, Piper Sandler lowered their price target on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, March 11th.

Institutional Investors Weigh In On Inozyme Pharma

Several hedge funds have recently bought and sold shares of INZY. Affinity Asset Advisors LLC boosted its holdings in shares of Inozyme Pharma by 40.7% during the fourth quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company’s stock worth $11,003,000 after purchasing an additional 1,150,000 shares during the period. Sanofi bought a new position in Inozyme Pharma during the 4th quarter valued at approximately $1,228,000. Renaissance Technologies LLC grew its stake in shares of Inozyme Pharma by 155.7% in the fourth quarter. Renaissance Technologies LLC now owns 421,399 shares of the company’s stock worth $1,167,000 after acquiring an additional 256,599 shares during the last quarter. Walleye Capital LLC bought a new stake in Inozyme Pharma during the 4th quarter valued at about $658,000. Finally, Pale Fire Capital SE lifted its stake in shares of Inozyme Pharma by 101.7% in the first quarter. Pale Fire Capital SE now owns 440,807 shares of the company’s stock worth $401,000 after buying an additional 222,270 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Stock Performance

Shares of INZY stock opened at $3.99 on Monday. The business has a 50 day simple moving average of $2.30 and a 200 day simple moving average of $1.95. The firm has a market capitalization of $257.60 million, a price-to-earnings ratio of -2.56 and a beta of 2.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. Inozyme Pharma has a 12-month low of $0.72 and a 12-month high of $6.24.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). On average, equities research analysts anticipate that Inozyme Pharma will post -1.59 EPS for the current year.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.